<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="555">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>5/10/2005</approvaldate>
  <actrnumber>ACTRN12605000589684</actrnumber>
  <trial_identification>
    <studytitle>Prostate Cancer: An internal, solid-malignancy model for vaccine therapy</studytitle>
    <scientifictitle>Phase II/III trial of immunotherapy based on cultured autologous dendritic cells presenting synthetic autologous Prostate Specific Membrane Antigen (PSMA) peptides with processed Keyhole Limpet Haemocyanin (KLH) as helper antigen for hormone refractory prostatic cancer to assess safety and effect on disease progression.</scientifictitle>
    <utrn />
    <trialacronym>NUQM00J1</trialacronym>
    <secondaryid>Queensland Institute of Medical Research (QIMR): QIMR P128</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hormone refractory prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single-blinded, 3 groups (randomised) examining two injection routes (intradermal and intravenous), of cultured autologous dendritic cells pulsed with soluble antigens.  6 injections with 4 weeks interval over 20 weeks.</interventions>
    <comparator>Control (saline)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>Measured at 20 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Efficacy</outcome>
      <timepoint>Measured at 20 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in a variety of in vitro and in vivo immunological parameters correlated  with clinical findings.</outcome>
      <timepoint>Assessed at 20 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Prostatic Cancer confirmed by biopsy, hormone refractory disease, HLA-A2+.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Bone metastasis, ECOG status&gt;1, PSA &lt;4ng/ml, Abnormal haematologic parameters, Abnormal liver and renal function paramenters, history of autoimmune disease or immunosuppressive therapy, previous radiotherapy, protatectomy, or  lymphadectomy, positive serology for HIV, Hep B or Hep C, Significant non-malignant disease, Psychiatric,  addictive or any conditions which compromise ability to participate in this trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Single blind, fixed allocation, sequential, centrally assigned randomisation, independently supervised by QA administration using a list concealed from clinical investigators</concealment>
    <sequence>No restriction method; sequence computer generated using the RANDOM module in the MS_DOS version of COMPUTER PROGRAMS FOR EPIDEMIOLOGISTS (PEPI) by J.H. Abramson and Paul M. Gahlinger.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>11/12/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Queensland Institute of Medical Research (QIMR)</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Queensland Cancer Fund</fundingname>
      <fundingaddress>553 Gregory Terrace Fortitude Valley 4004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Urological Society of Australia</fundingname>
      <fundingaddress>Suite 512 Eastpoint, 180 Ocean St, Edgcliff 2027</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>philanthropic sources</fundingname>
      <fundingaddress>Queensland Institute of Medical Research, 300 Herston Rd, Herston 4006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Institute of Medical Research</ethicname>
      <ethicaddress>Brisbane, QLD, 4006</ethicaddress>
      <ethicapprovaldate>8/12/2000</ethicapprovaldate>
      <hrec>EC 00278</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Womens' Hospital</ethicname>
      <ethicaddress>Herston, Q 4029</ethicaddress>
      <ethicapprovaldate>24/05/2000</ethicapprovaldate>
      <hrec>EC00172</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Schmidt</name>
      <address>Queensland Institute of Medical Research
300 Herston Road
Herston QLD 4006</address>
      <phone>+61 7 33620313</phone>
      <fax>+61 7 38453510</fax>
      <email>Chris.Schmidt@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Betty Scells</name>
      <address>University of Queensland
Clinical Sciences Building
Royal Brisbane and Womens' Hospital
Herston QLD 4006</address>
      <phone>+61 7 33655233</phone>
      <fax>+61 7 33655559</fax>
      <email>b.scells@mailbox.uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Agnieszka Mitchell</name>
      <address>Queensland Institute of Medical Research, 300 Herston Rd, Herston 4006</address>
      <phone>07 3362 0241</phone>
      <fax>07 3362 0109</fax>
      <email>Agnieszka.Mitchell@qimr.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>